Compare BridgeBio Pharma Inc (BBIO) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Coinbase Global, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Coinbase Global, Inc. trades at $148.8 (market cap $39.23B). The key difference: Coinbase Global, Inc. is far larger — about 2.4× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | COIN | |
|---|---|---|
Market Cap | $16.61B | $39.23B |
Sector | Health | Technology |
52-Week High | $90.17 | $387.27 |
52-Week Low | $47.29 | $141.09 |
Enterprise Value | $18.16B | $36.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
COIN trades at $153.6, up 5.63% in the past 24 hours, but technical indicators signal a bearish trend with resistance near $157. The company reported Q2 2026 revenue of $1.22 billion, missing estimates, and a net loss of $359.5 million, though adjusted EBITDA remained positive for the 14th consecutive quarter. Analyst consensus is a Buy with a $207.20 price target, but recent news highlights crypto market weakness and a Zacks Strong Sell rating on August 6, 2026.
The outlook is mixed: strong cash flow and market share growth offer upside, but consecutive earnings misses and high valuation ratios pose risks. Investors face volatility from crypto market dependence and competitive pressures, requiring caution despite Wall Street's bullish average target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
